MedTrace Logo

Prevention of Severe Postpartum Hypertension

NCT02450773 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-05-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether postpartum administration of furosemide to women with antepartum hypertensive disorders (gestational hypertension, preeclampsia) or elevated blood pressure in the first 24 hours following delivery reduces severe postpartum hypertension.

Conditions

Interventions

DRUG

Furosemide

40 mg furosemide on postpartum day 1-6

DRUG

Potassium chloride

20 meq potassium chloride on postpartum day 1-6

DRUG

Placebo #1

Placebo (for furosemide)

DRUG

Placebo #2

Placebo (for KCl)

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Methodius G Tuuli, MD, MPH · Indiana University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02450773 on ClinicalTrials.gov